Pancreatic ductal adenocarcinoma (PDAC) occurs mainly in people older than 50 years of
age. Although great strides have been taken in treating PDAC over the past decades its …

Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal types of cancer in the
United States. Surgical resection remains the only curative treatment, but fewer than 20% of …

The integration of microfluidics and cell biology has reached a significant milestone with the
development of “organ-on-chips”, smart technological platforms that, once applied to the …

The effects of blocking the epidermal growth factor receptor (EGFR) in acute kidney injury
(AKI) are controversial. Here we investigated the renoprotective effect of erlotinib, a selective …

Overexpression of epidermal growth factor receptors (EGFR) occurs in> 90% of pancreatic
ductal adenocarcinomas (PDACs) and is associated with a poorer prognosis. A systematic …

Introduction: Since the pioneering work of Judah Folkman, the discovery of bevacizumab
has introduced the use of anti-angiogenic agents as a new modality for the treatment of …

The prognosis for patients with pancreatic cancer remains poor despite increased
knowledge of its molecular genetics and histopathological progression. Pancreatic cancer is …

Purpose: This phase 1b dose-escalation study assessed safety, tolerability, and
pharmacokinetics of ganitumab, a fully human monoclonal antibody against the insulin-like …

Background The relative success of cisplatin-based chemotherapy regimens for PDAC in
clinical trials warrants a review of the literature to assess the cumulative results. This study …

Neurotoxicity is a severe side effect of platinum compounds used for cancer chemotherapy
such as Cisplatin. This neurotoxicity leads to severe cognitive and nervous dysfunction …